George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
It wouldn’t surprise me if we get another news release very soon on any one of the compounds currently in trial or under evaluation from major pharmaceutical.
Exciting time for scancell and shareholders.
Ruck, I wasn’t questioning your figures, I’m quoting the industry standard risk adjusted NPV that trinity used.
From what I can see, they are valuing the company as if it’s current trials were still in the ore clinical phase.
Although there valuation for scancell is somewhat 40% higher than today it is still considerably undervalued by industry standard raNPV
TD have outdated information.
The stated 10% chance applies to pre clinical drug candidates.
Scancell have three active trials which are by definition well past the pre clinical stage.
It always amazes me how some so called experts can get their figures from outdated research so wrong.
We hit 27p last year with no trials running and we now have 3 trials on the go.
I can honestly say I expect the share price to easily exceed 27p this year.
Exciting times not only for the shareholders but for cancer patients as well.
Crumbs, I know what you mean. We all know scancell, but this trial and it’s implementation is in a completely different class way above anything scancell has attempted to date.
This is the time of Scancell and I’m sure they are about to prove it to the world.
The pre clinical data is unprecedented and will hopefully provide immeasurable benefits to millions worldwide.
Although, with 20 centres recruiting and the the trial already having the green light to start from today, there is no reason why we couldn’t get news this week saying they have recruited already.
WTP, it looks highly likely from the comments from the principal investigator combined with those from the company that we should expect first patient dosed in about 7 days to 28 days.
My money is on 21 days from today.